RxDoctor Payments Data

Haley Kielbas

Physician Assistant · Grafton, VANPI 1073274460

Payments from drug & device makers

$2,700in general payments, 2019–2025

Across 111 payments — averaging $24.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$631
  • Novo Nordisk$324
  • Pfizer$309
  • Shield Therapeutics Inc$249
  • AstraZeneca$239
  • GSK$212
  • plus $737 from 12 others

What the payments were for

  • Food & beverage$2,700100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,700 in reported general payments places this provider in the 85th percentile of 3,376 physician assistant providers in Virginia.

See all physician assistant providers in Virginia

Medicare billing

Part B allowed, 2024
$111,502
Medicare patients
244
Services billed
3,335

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide61$71,275
EliquisApixaban74$57,540
JardianceEmpagliflozin47$42,887
TrulicityDulaglutide24$28,127
RybelsusSemaglutide19$26,878
FarxigaDapagliflozin Propanediol14$15,056
MounjaroTirzepatide11$11,191
MyrbetriqMirabegron11$9,573
BelsomraSuvorexant12$5,085
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$4,438
PremarinEstrogens, Conjugated13$3,809
Atorvastatin Calcium291$2,320
Duloxetine Hcl46$1,483
Lidocaine19$1,384
Levothyroxine Sodium122$1,219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$324$98,15380 claims
PfizerEliquis, Premarin$309$61,34987 claims
Boehringer IngelheimJardiance$30$42,88747 claims
Lilly USA, LLCTrulicity, Mounjaro$631$39,31735 claims
AstraZenecaFarxiga$239$15,05614 claims
Astellas Pharma US IncMyrbetriq$36$9,57311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,376 physician assistant providers in Virginia.

Other physician assistant in Grafton

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →